CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms

In mCRPC patients eligible for chemotherapy, the therapy sequence should be chosen so that the patients also receive cabazitaxel. A direct therapy sequence with two ARTAs should be avoided or, at least, only considered if other substances are contraindicated.